ストックスクリーナーアプリを入手
5.08
9.48%
0.44
アフターアワーズ：
5.09
0.010
+0.20%
前日終値:
$4.64
開ける：
$4.58
24時間の取引高:
287.20K
Relative Volume:
1.02
時価総額：
$110.83M
収益：
-
当期純損益:
$-57.59M
株価収益率:
-1.918
EPS:
-2.6486
ネットキャッシュフロー:
$-54.27M
1週間 パフォーマンス:
+29.26%
1か月 パフォーマンス:
-0.20%
6か月 パフォーマンス:
-63.53%
1年 パフォーマンス:
-36.10%
1日の値動き範囲:
$4.58
$5.1454
1週間の範囲:
$3.80
$5.1454
52週間の値動き範囲:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
名前
Aardvark Therapeutics Inc
セクター
電話
(858) 225-7696
住所
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
5.08 | 101.23M | 0 | -57.59M | -54.27M | -2.6486 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | ダウングレード | Stifel | Buy → Hold |
| 2026-01-28 | 開始されました | B. Riley Securities | Buy |
| 2025-12-23 | 開始されました | Oppenheimer | Outperform |
| 2025-12-12 | 開始されました | William Blair | Outperform |
| 2025-12-03 | 開始されました | Raymond James | Strong Buy |
| 2025-11-07 | 開始されました | BTIG Research | Buy |
| 2025-09-29 | 開始されました | Stifel | Buy |
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 開始されました | BofA Securities | Buy |
| 2025-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 開始されました | Morgan Stanley | Overweight |
| 2025-03-10 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aardvark Therapeutics Inc (AARD) 最新ニュース
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
AARD Technical Analysis & Stock Price Forecast - Intellectia AI
AARD Options Chain — NASDAQ:AARD - TradingView — Track All Markets
AARD Options Volatility — NASDAQ:AARD - TradingView — Track All Markets
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56% - Intellectia AI
Aardvark Therapeutics Shares Plunge After Trial Halt - Intellectia AI
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Finviz
AARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman - GlobeNewswire Inc.
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Prader-Willi Syndrome Market Size in the 7MM was ~USD 600 million in 2023 and expected to grow by 2034, reveals DelveInsight - Barchart.com
[EFFECT] Aardvark Therapeutics, Inc. SEC Filing - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out | NDAQ:AARD | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aardvark Therapeutics (AARD) price target decreased by 43.62% to 18.77 - MSN
Aardvark ups to $150M ATM sale with Piper Sandler (NASDAQ: AARD) - stocktitan.net
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Investors to Connect - ACCESS Newswire
Why Aardvark Therapeutics (AARD) paused late-stage ARD-101 trials after cardiac findings - msn.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings - Insider Monkey
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest - MarketBeat
Why is Aardvark Therapeutics stock sinking Monday? - MSN
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
US Stocks Recap: Does Aardvark Therapeutics Inc align with a passive investing strategyWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Heart activity changes prompted pause in trial of ARD-101 in PWS - Prader-Willi Syndrome News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
Decliners Report: Can Aardvark Therapeutics Inc outperform under higher oil prices2026 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Stockholders to Connect - ACCESS Newswire
Aardvark Therapeutics, Inc. Files Form 8-K Announcing Entry Into Material Definitive Agreement – Company Details, Nasdaq Symbol AARD, and Contact Information - Minichart
Jones Trading cuts Aardvark Therapeutics stock price target on trial delay - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph
User - The Chronicle-Journal
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path By Investing.com - Investing.com Australia
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path - Investing.com
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating By Investing.com - Investing.com India
AARD Stock Price and Chart — NASDAQ:AARD - TradingView
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating - investing.com
B.Riley cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com South Africa
BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics Inc. has officially signed an equity distribution agreement with Piper Sandler. - Bitget
Aardvark Therapeutics Inc (AARD) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):